When did Niagen Bioscience, Inc. Common Stock report Q1 2025 earnings?

Niagen Bioscience, Inc. Common Stock (NAGE) reported Q1 2025 earnings on May 7, 2025 after market close.

What were Niagen Bioscience, Inc. Common Stock's Q1 2025 revenue and EPS?

Niagen Bioscience, Inc. Common Stock reported revenue of $30.5M and diluted EPS of $0.04 for Q1 2025.

Did Niagen Bioscience, Inc. Common Stock beat estimates in Q1 2025?

Revenue beat the consensus estimate of $27.1M by $3.4M. EPS beat the consensus estimate of $0.02 by $0.02.

Where can I find Niagen Bioscience, Inc. Common Stock's Q1 2025 SEC filings?

You can read the 10-Q periodic report (0001628280-25-023127) directly on SEC EDGAR. The filing index links above go to sec.gov.

Niagen Bioscience, Inc. Common Stock NAGE Q1 2025 earnings

Reported May 7, 2025 · After market close

Revenue$30.5MBeat by $3.4M Diluted EPS$0.04Beat by $0.02

Revenue estimate$27.1M

EPS estimate$0.02

Next report

Aug 5, 2026 (in a month)

Revenue estimate$31.7M

EPS estimate$0.01

Financials

Q1 2025

Income statement

See full

Revenue$30.5M+37.6%

Gross profit$19.3M+43.7%

Operating income$4.8M+753%

Net income$5.1M+1,129%

EPS (diluted)$0.06+700%

Balance sheet

See full

Cash & equivalents$55.6M+102%

Total debt$3.5M+9.2%

Total equity$55.3M+91.2%

Total assets$81.3M+50.4%

Cash flow

See full

Operating cash flow$7.9M+2,572%

Valuation & ratios

Profitability

See full

Gross margin62.5%+1.5pp

Operating margin12.3%+9.4pp

Net margin13.1%+10.4pp

Returns & leverage

See full

Return on equity33.5%+26.2pp

Debt / equity0.1×0.0×

Current ratio3.7×+1.1×

Segments

By segment

See full

Consumer Products segment$21.5M+23.9%

Ingredients segment$8.2M+99.8%

Analytical Reference Standards and Services segment$811.0K+13.6%

Pharmaceuticals segment-—

Versus estimates

Revenue

Q1 2026$31.5MBeat by $444.0K Q4 2025$33.8MBeat by $2.1M Q3 2025$34.0MBeat by $2.9M Q2 2025$31.1MBeat by $354.8K

Q1 2025$30.5MBeat by $3.4M

Q4 2024$29.1MBeat by $2.4M

Diluted EPS

Q1 2026$0.07Beat by $0.01 Q4 2025$0.03Beat by $0.01 Q3 2025$0.05Beat by $0.04 Q2 2025$0.04Beat by $0.02

Q1 2025$0.04Beat by $0.02

Q4 2024$0.03Beat by $0.01

Ask the moment Niagen Bioscience, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Niagen Bioscience, Inc. Common Stock report Q1 2025 earnings?: Niagen Bioscience, Inc. Common Stock (NAGE) reported Q1 2025 earnings on May 7, 2025 after market close.
What were Niagen Bioscience, Inc. Common Stock's Q1 2025 revenue and EPS?: Niagen Bioscience, Inc. Common Stock reported revenue of $30.5M and diluted EPS of $0.04 for Q1 2025.
Did Niagen Bioscience, Inc. Common Stock beat estimates in Q1 2025?: Revenue beat the consensus estimate of $27.1M by $3.4M. EPS beat the consensus estimate of $0.02 by $0.02.
Where can I find Niagen Bioscience, Inc. Common Stock's Q1 2025 SEC filings?: You can read the 10-Q periodic report (0001628280-25-023127) directly on SEC EDGAR. The filing index links above go to sec.gov.